Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1194066 | 0.79 | BTK (0.58) | ALDH1A1NPC1HPGDL3MBTL1MEN1 | |
| SCHEMBL1133436 | 0.78 | GAA (0.50) | ALDH1A1NPC1TP53HPGDL3MBTL1 | |
| SCHEMBL18075675 | 0.78 | GCK (0.33) | ALDH1A1NPC1TP53HPGDL3MBTL1 | |
| SCHEMBL20595279 | 0.74 | PDE4A (0.46) | ALDH1A1TP53MEN1KMT2APDE3B | |
| SCHEMBL7454459 | 0.74 | PDE3B (0.50) | ALDH1A1HPGDL3MBTL1PDE3BPDE3A | |
| SCHEMBL27568206 | 0.74 | ALDH1A1 (0.58) | ALDH1A1NPC1HPGDL3MBTL1MEN1 | |
| SCHEMBL916879 | 0.73 | POLB (0.44) | ALDH1A1NPC1TP53HPGDL3MBTL1 | |
| SCHEMBL14340862 | 0.72 | HPGD (0.45) | ALDH1A1NPC1TP53HPGDSMN1; SMN2 | |
| SCHEMBL6294683 | 0.72 | KMT2A (0.58) | ALDH1A1HPGDKMT2ABTK | |
| SCHEMBL30060621 | 0.72 | KMT2A (0.58) | ALDH1A1HPGDKMT2ABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | SANOFI (FR) | 2012-08-30 | — | — | US | claimed |
| EP-2464632-A1 | PYRIMIDONE DERIVATIVES USED AS TAU PROTEIN KINASE 1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-06-20 | — | — | EP | claimed |
| EP-2033963-A1 | Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives | Sanofi-Aventis (FR) | 2009-03-11 | — | — | EP | claimed |
| EP-2001863-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-12-17 | — | — | EP | claimed |
| WO-2007119463-A1 | 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-25 | — | — | WO | claimed |
| CN-119894896-A | Inhibitors of green peroxidase | 阿斯利康(瑞典)有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | SANOFI (FR) | 2012-08-30 | — | — | US | disclosed |
| EP-2464632-A1 | PYRIMIDONE DERIVATIVES USED AS TAU PROTEIN KINASE 1 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-20 | — | — | US | disclosed |
| EP-2033963-B1 | Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2011-02-16 | — | — | EP | disclosed |
| EP-1603910-B1 | SUBSTITUTED 2-(DIAZA-BICYCLO-ALKYL)-PYRIMIDONE DERIVATIVES | SANOFI AVENTIS (FR) | 2009-08-26 | — | — | EP | disclosed |
| EP-2033963-A1 | Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives | Sanofi-Aventis (FR) | 2009-03-11 | — | — | EP | disclosed |
| US-7452897-B2 | Use of substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives for the treatment of neurodegenerative diseases | SANOFI-AVENTIS (FR) | 2008-11-18 | — | — | US | disclosed |
| EP-1910320-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-20070167455-A1 | USE OF SUBSTITUTED 2-(DIAZA-BICYCLO-ALKYL)-PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | disclosed |
| WO-2007011065-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-25 | — | — | WO | disclosed |
| EP-1603910-A1 | SUBSTITUTED 2-(DIAZA-BICYCLO-ALKYL)-PYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004078759-A1 | SUBSTITUTED 2-(DIAZA-BICYCLO-ALKYL)-PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220591-A1 | PYRIMIDONE COMPOUNDS | MAPT, PRNP, PSEN1 | ALDH1A1 1701/4885NPC1 1063/4885TP53 1166/4885 |
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | ALDH1A1 1251/4885NPC1 1685/4885TP53 1955/4885 |
| US-20070167455-A1 | USE OF SUBSTITUTED 2-(DIAZA-BICYCLO-ALKYL)-PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PSEN2, PSEN1, GSK3A | ALDH1A1 322/4885NPC1 343/4885TP53 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.